{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T01:08:01Z","timestamp":1775956081019,"version":"3.50.1"},"reference-count":19,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4,5]]},"abstract":"<jats:p>AmBisome (liposomal amphotericin B) is used for prophylaxis and treatment of fungal infections, treatment of visceral leishmaniasis, and more recently, treatment of cutaneous leishmaniasis. Although the package insert cites neurologic toxicities in up to 20% of cases, review of the literature did not reveal any specific cases describing this side effect, particularly in a patient without comorbidities. We describe a healthy 38-year-old male treated with liposomal amphotericin B for cutaneous leishmaniasis acquired during military duties in Iraq. Shortly after completion of his treatment course, he reported memory difficulties and confusion. Further evaluation revealed no other source, and his cognitive issues were attributed to liposomal amphotericin B toxicity. These issues resolved over a few weeks, which is consistent with data about the drug's tissue penetration and metabolism available in the literature. This is a potential side effect of liposomal amphotericin B that can be observed in otherwise healthy patients.<\/jats:p>","DOI":"10.4269\/ajtmh.2011.10-0662","type":"journal-article","created":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T13:23:23Z","timestamp":1301664203000},"page":"566-568","source":"Crossref","is-referenced-by-count":13,"title":["Central Nervous System Toxicity Associated with Liposomal Amphotericin B Therapy for Cutaneous Leishmaniasis"],"prefix":"10.4269","volume":"84","author":[{"given":"Jessie S.","family":"Glasser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clinton K.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"key":"R1","series-title":"Lancet Infect Dis","first-page":"581","article-title":"Cutaneous leishmaniasis","volume":"7","author":"Reithinger","year":"2007"},{"key":"R2","series-title":"J Infect","first-page":"e261","article-title":"Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin","volume":"51","author":"Paradisi","year":"2005"},{"key":"R3","series-title":"Br J Dermatol","first-page":"203","article-title":"Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis","volume":"153","author":"Brown","year":"2005"},{"key":"R4","series-title":"Acta Trop","first-page":"127","article-title":"Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients","volume":"92","author":"Amato","year":"2004"},{"key":"R5","series-title":"J Am Acad Dermatol","first-page":"612","article-title":"Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis","volume":"56","author":"Solomon","year":"2007"},{"key":"R6","series-title":"J Trop Pediatr","first-page":"122","article-title":"Successful treatment of childhood cutaneous leishmaniasis with liposomal amphotericin B: report of two cases","volume":"56","author":"Del Rosal","year":"2009"},{"key":"R7","series-title":"Am J Trop Med Hyg","first-page":"1028","article-title":"Liposomal amphotericin B for treatment of cutaneous leishmaniasis","volume":"83","author":"Wortmann","year":"2010"},{"key":"R8","series-title":"Clin Infect Dis","first-page":"42","article-title":"U.S. Food and Drug Administration approval of AmBisome (Liposomal Amphotericin B) for treatment of visceral leishmaniasis","volume":"28","author":"Meyerhoff","year":"1999"},{"key":"R9","series-title":"BMJ","first-page":"230","article-title":"Neurological manifestations after amphotericin B therapy","volume":"1","author":"Haber","year":"1962"},{"key":"R10","series-title":"Psychosomatics","first-page":"1076","article-title":"Delirium and depression associated with amphotericin B","volume":"23","author":"Weddington","year":"1982"},{"key":"R11","series-title":"Antimicrob Agents Chemother","first-page":"2420","article-title":"Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits","volume":"46","author":"Clemons","year":"2002"},{"key":"R12","series-title":"Chemotherapy","first-page":"271","article-title":"Influence of the progression of cryptococcal meningitis on brain Penetration and efficacy of AmBisome in a murine model","volume":"52","author":"Takemoto","year":"2006"},{"key":"R13","series-title":"J Antimicrob Chemother","first-page":"1153","article-title":"Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion","volume":"57","author":"Vogelsinger","year":"2006"},{"key":"R14","series-title":"Drugs","first-page":"585","article-title":"Liposomal amphotericin B therapeutic use in the management of fungal infections and visceral leishmaniasis","volume":"55","author":"Coukell","year":"1998"},{"key":"R15","series-title":"J Antimicrob Chemother","first-page":"941","article-title":"Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B","volume":"59","author":"Smith","year":"2007"},{"key":"R16","series-title":"Pharm Res","first-page":"1494","article-title":"Safety, toxicokinetic and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): a 91-day study in rats","volume":"17","author":"Bekersky","year":"2000"},{"key":"R17","series-title":"Clin Infect Dis","first-page":"1155","article-title":"A randomized, double-blind comparative trial evaluating the safety of the liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia","volume":"31","author":"Wingard","year":"2000"},{"key":"R18","series-title":"Antimicrob Agents Chemother","first-page":"3774","article-title":"Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B","volume":"47","author":"Larabi","year":"2003"},{"key":"R19","series-title":"Lancet Infect Dis","first-page":"763","article-title":"Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980\u20132004","volume":"5","author":"Olliaro","year":"2005"}],"container-title":["The American Society of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/84\/4\/article-p566.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/84\/4\/article-p566.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/84\/4\/article-p566.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T19:55:26Z","timestamp":1723060526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/84\/4\/article-p566.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,5]]},"references-count":19,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.2011.10-0662","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"value":"0002-9637","type":"print"},{"value":"1476-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,5]]}}}